Abstract：Objective To investigate the clinical efficacy of Sacubitril Valsartan Sodium Tablets in the treatment of coronary heart disease complicated with chronic heart failure (CHF) and the effect on the level of N-terminal pro-Btype natriuretic peptide (NT-proBNP) and cardiac function in patients. Methods A total of 126 patients with coronary heart disease and CHF admitted to Longkou People′s Hospital from January 2018 to January 2020 were selected as the research subjects. According to random number table method，they were divided into control group and observation group，63 cases in each group. The control group was treated with conventional treatment，and the observation group was treated with Sacubitril Valsartan Sodium Tablets on the basis of the control group，and continued to take medicine for 3 months. Clinical efficacy，NT-proBNP level，cardiac function indexes (left ventricular ejection fraction [LVEF]，stroke output [SV]，cardiac output [CO])，6-min walking distance，quality of life and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate of observation group was higher than control group，the difference was statistically significant (P＜0.05). There was no significant difference in NT-proBNP level and cardiac function indexes between the two groups before treatment (P＞0.05). The level of NT-proBNP after treatment was lower than before treatment，while LVEF，SV and CO were higher than before treatment，the differences were statistically significant (P＜0.05). After treatment，the level of NT-proBNP in the observation group was lower than that in the control group，while LVEF，SV and CO were higher than those in the control group，the differences were statistically significant (P＜0.05). There were no significant differences in walking distance and Minnesota heart failure quality of life scale (MLHFQ) score before treatment between the two groups (P＞0.05). The walking distance 6 min after treatment was longer than before treatment，and the MLHFQ score was lower than before treatment，the differences were statistically significant (P＜0.05). The observation group had longer walking distance 6 min after treatment than the control group，and the MLHFQ score was lower than the control group，the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion Sacubitril Valsartan Sodium Tablets can enhance the therapeutic effect of coronary heart disease complicated with CHF，reduce the serum NT-proBNP level，accelerate the recovery of cardiac function，improve the quality of life of patients，and it is safe and reliable.
京公网安备 11010502046607号